Exact claim · Version 1 · Reviewed July 31, 2026

“Melanotan II protects you from sun damage or lowers skin cancer risk.”

A verdict on this wording and scope, not a universal grade for Melanotan II.

01 · Verdict

Misleading

No trial of any kind has tested sunburn, ultraviolet damage, or skin cancer as an endpoint. The published record runs the other way: melanoma and dysplastic naevus case reports, a review counting four melanomas emerging from existing moles during or shortly after melanotan use, and an approved melanocortin-1 agonist whose label calls for twice-yearly full-body skin examination because it can darken pre-existing naevi.

Evidence basis: No reliable human outcome evidence
Scope: All protective or preventive framing, including the comparison with sunbeds.
Category: Safety

02 · Primary record

Check the attached evidence

01Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a reviewPubMed · International Journal of Dermatology · Science review · 2017
Supports the corrective verdict 02Melanoma associated with the use of melanotan-IIPubMed · Dermatology · Reference · 2014
Supports the corrective verdict 03Melanotan II nasal spray: a possible risk factor for oral mucosal malignant melanoma?PubMed · International Journal of Oral and Maxillofacial Surgery · Reference · 2025
Supports the corrective verdict 04SCENESSE (afamelanotide) prescribing informationDailyMed · U.S. National Library of Medicine · Drug label · 2026
Supports the corrective verdict

Editorial review: Internal editorial review recorded
Responsible editor: Anthony Treviso · Founder and responsible editor
Clinical-review boundary: Not independently medically reviewed.